New Ph. Eur. Chapter on Essential Oils
Recommendation

Thursday, 29 October 2026 9 .00 - 17.15 h
AI/ML-based Methods for Optimizing Pharmaceutical Research Processes
The general Ph. Eur. monograph on Essential oils has been published for comment in the recent issue of Pharmeuropa (32.2). The monograph has undergone complete revision. As basis for the elaboration of monographs on essential oils, a new Ph. Eur. chapter 5.30. Monographs on essential oils is proposed in addition. The public deadline is 30 June 2020.
Contaminants in Essential Oils and Skip Testing
Herbal drugs used for the preparation of essential oils have to comply with the requirements of any relevant monograph in the Ph. Eur. (for example general Ph. Eur. Monograph Herbal Drugs). In addition, the draft monograph on essential oils prescribes limits for the following tests on contaminants:
Heavy metals (Ph. Eur. 2.4.27)
- cadmium: maximum 1.0 ppm;
- lead: maximum 5.0 ppm;
- mercury: maximum 0.1 ppm.
Where necessary, limits for other heavy metals may be required.
Pesticide residues (Ph. Eur. 2.8.13), Aflatoxin B1 (Ph. Eur. 2.8.18) and Microbiological quality (Ph. Eur. 5.1.4 or 5.1.8): Where justified and authorized, individual testing of every batch may not be necessary.
According to the proposed new Ph. Eur. chapter 5.30. Monographs on essential oils, the "risk of the presence of contaminants in essential oils is closely linked to the type of contaminants, the origin of the plant material used for production and the production processes". However, contaminants such as heavy metals, pesticides, and aflatoxins are not considered a critical issue for essential oils. They need to be considered in individual cases based on a risk assessment. In particular, the risk is higher for cold-pressed essential oils than for distilled ones.
In general, Ph. Eur. chapter 2.8.13. Pesticide residues is applicable to essential oils. "Nevertheless, it has been shown that the levels of pesticides present in essential oils obtained by distillation rarely exceed the prescribed limits, which may justify skip testing".
More information can be found on the Pharmeuropa website.
Related GMP News
29.09.2026FDA wants to Advance the Development of Herbal Medicinal Products
29.09.2026Ph. Eur. Draft for Comment: 2.8.18. Determination of Aflatoxin B1 in Herbal Drugs
29.09.2026Can Cannabis Flowers be pre-dried in Accordance with GACP?
29.09.2026Water Determination in Herbal Drugs
10.09.2026New Information Sheet regarding Cannabis for Medical Purposes
10.09.2026EMA Reflection Paper on Safety Signals for Herbal Medicinal Products


